OSBPL7-IN-1

Cat. No.:	HY-143200		
CAS No.:	1269826-44	-9	
Molecular Formula:	C ₂₀ H ₁₉ Cl ₂ F ₃ N	1 ₂ 0 ₃	
Molecular Weight:	463.28		
Target:	Others		
Pathway:	Others		
Storage:	Powder	-20°C	3 years
	In solvent	-80°C	6 months
		-20°C	1 month

®

MedChemExpress

SOLVENT & SOLUBILITY

In Vitro DMS	DMSO : 125 mg/mL (269.82 mM; ultrasonic and warming and heat to 60°C)				
		Solvent Concentration	1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM	2.1585 mL	10.7926 mL	21.5852 mL
		5 mM	0.4317 mL	2.1585 mL	4.3170 mL
		10 mM	0.2159 mL	1.0793 mL	2.1585 mL
	Please refer to the so	lubility information to select the ap	propriate solvent.		
In Vivo	1. Add each solvent o Solubility: ≥ 2.08 n	one by one: 10% DMSO >> 90% co ng/mL (4.49 mM); Clear solution	rn oil		

BIOLOGICAL ACTIV	ТТ
Description	OSBPL7-IN-1 is an orally active oxysterol binding protein like 7 (OSBPL7) inhibitor. OSBPL7-IN-1 promotes an increase of ABCA1 at the plasma membrane without affecting mRNA expression ^[1] .
IC ₅₀ & Target	OSBPL7 ^[1] ABCA1 ^[1]
In Vitro	OSBPL7-IN-1 (compound G or Cpd G; 1-10 μM) increase plasma membrane ATP-binding cassette transporter (ABCA1) in cultured human podocytes, and significantly increase ABCA1-dependent cholesterol efflux ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	OSBPL7-IN-1 (100 mg/kg; oral gavage; daily; for 28 days) treatment normalizes proteinuria and prevents renal function decline in mouse models of proteinuric kidney disease ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Product Data Sheet

ОНО

CI

CI

Animal Model:	Female Balb/c mice induced by Adriamycin (ADR) ^[1]
Dosage:	100 mg/kg
Administration:	Oral gavage; daily; for 28 days
Result:	Normalized proteinuria, and significantly reduced renal fibrosis and renal functional decline.

REFERENCES

[1]. Matthew B Wright, et al. Compounds targeting OSBPL7 increase ABCA1-dependent cholesterol efflux preserving kidney function in two models of kidney disease. Nat Commun. 2021 Aug 2;12(1):4662.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA